Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Ovarian morphology and function during growth hormone therapy of short girls born small for gestational age

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{3ca90aad2066460f9c8a9574364f424d,
title = "Ovarian morphology and function during growth hormone therapy of short girls born small for gestational age",
abstract = "OBJECTIVE: To study the effect of growth hormone (GH) treatment on ovarian and uterine morphology and function in short, prepubertal small-for-gestational-age (SGA) girls.DESIGN: A multinational, randomized controlled trial on safety and efficacy of GH therapy in short, prepubertal children born SGA.SETTING: Not applicable.PATIENT(S): A subgroup of 18 Danish girls born SGA included in North European SGA Study (NESGAS).INTERVENTION(S): One year of GH treatment (67 μg/kg/day) followed by 2 years of randomized GH treatment (67 μg/kg/day, 35 μg/kg/day, or IGF-I titrated).MAIN OUTCOME MEASURE(S): Data on anthropometrics, reproductive hormones, and ultrasonographic examination of the internal genitalia were collected during 36 months of GH treatment.RESULT(S): Uterine and ovarian volume increased significantly during 3 years of treatment (64{\%} and 110{\%}, respectively) but remained low within normal reference ranges. Ovarian follicles became visible in 58{\%} after 1 year compared with 28{\%} before GH therapy. Anti-M{\"u}llerian hormone increased significantly during the 3 years of GH therapy but remained within the normal range. Precocious puberty was observed in one girl; another girl developed multicystic ovaries.CONCLUSION(S): GH treatment was associated with statistically significant growth of the internal genitalia, but remained within the normal range. As altered pubertal development and ovarian morphology were found in 2 of 18 girls, monitoring of puberty and ovarian function during GH therapy in SGA girls is prudent. Altogether, the findings are reassuring. However, long-term effects of GH treatment on adult reproductive function remain unknown.CLINICAL TRIAL REGISTRATION NUMBER: EudraCT 2005-001507-19.",
author = "Jeanette Tinggaard and Jensen, {Rikke Beck} and Karin Sundberg and Niels Birkeb{\ae}k and Peter Christiansen and Annie Ellermann and Kirsten Holm and Jeppesen, {Eva Mosfeldt} and Britta Kremke and Pawel Marcinski and Carsten Pedersen and Nina Saurbrey and Ebbe Thisted and Main, {Katharina M} and Anders Juul",
note = "Copyright {\circledC} 2014 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.",
year = "2014",
month = "12",
doi = "10.1016/j.fertnstert.2014.09.014",
language = "English",
volume = "102",
pages = "1733--41",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier Inc",
number = "6",

}

RIS

TY - JOUR

T1 - Ovarian morphology and function during growth hormone therapy of short girls born small for gestational age

AU - Tinggaard, Jeanette

AU - Jensen, Rikke Beck

AU - Sundberg, Karin

AU - Birkebæk, Niels

AU - Christiansen, Peter

AU - Ellermann, Annie

AU - Holm, Kirsten

AU - Jeppesen, Eva Mosfeldt

AU - Kremke, Britta

AU - Marcinski, Pawel

AU - Pedersen, Carsten

AU - Saurbrey , Nina

AU - Thisted, Ebbe

AU - Main, Katharina M

AU - Juul, Anders

N1 - Copyright © 2014 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

PY - 2014/12

Y1 - 2014/12

N2 - OBJECTIVE: To study the effect of growth hormone (GH) treatment on ovarian and uterine morphology and function in short, prepubertal small-for-gestational-age (SGA) girls.DESIGN: A multinational, randomized controlled trial on safety and efficacy of GH therapy in short, prepubertal children born SGA.SETTING: Not applicable.PATIENT(S): A subgroup of 18 Danish girls born SGA included in North European SGA Study (NESGAS).INTERVENTION(S): One year of GH treatment (67 μg/kg/day) followed by 2 years of randomized GH treatment (67 μg/kg/day, 35 μg/kg/day, or IGF-I titrated).MAIN OUTCOME MEASURE(S): Data on anthropometrics, reproductive hormones, and ultrasonographic examination of the internal genitalia were collected during 36 months of GH treatment.RESULT(S): Uterine and ovarian volume increased significantly during 3 years of treatment (64% and 110%, respectively) but remained low within normal reference ranges. Ovarian follicles became visible in 58% after 1 year compared with 28% before GH therapy. Anti-Müllerian hormone increased significantly during the 3 years of GH therapy but remained within the normal range. Precocious puberty was observed in one girl; another girl developed multicystic ovaries.CONCLUSION(S): GH treatment was associated with statistically significant growth of the internal genitalia, but remained within the normal range. As altered pubertal development and ovarian morphology were found in 2 of 18 girls, monitoring of puberty and ovarian function during GH therapy in SGA girls is prudent. Altogether, the findings are reassuring. However, long-term effects of GH treatment on adult reproductive function remain unknown.CLINICAL TRIAL REGISTRATION NUMBER: EudraCT 2005-001507-19.

AB - OBJECTIVE: To study the effect of growth hormone (GH) treatment on ovarian and uterine morphology and function in short, prepubertal small-for-gestational-age (SGA) girls.DESIGN: A multinational, randomized controlled trial on safety and efficacy of GH therapy in short, prepubertal children born SGA.SETTING: Not applicable.PATIENT(S): A subgroup of 18 Danish girls born SGA included in North European SGA Study (NESGAS).INTERVENTION(S): One year of GH treatment (67 μg/kg/day) followed by 2 years of randomized GH treatment (67 μg/kg/day, 35 μg/kg/day, or IGF-I titrated).MAIN OUTCOME MEASURE(S): Data on anthropometrics, reproductive hormones, and ultrasonographic examination of the internal genitalia were collected during 36 months of GH treatment.RESULT(S): Uterine and ovarian volume increased significantly during 3 years of treatment (64% and 110%, respectively) but remained low within normal reference ranges. Ovarian follicles became visible in 58% after 1 year compared with 28% before GH therapy. Anti-Müllerian hormone increased significantly during the 3 years of GH therapy but remained within the normal range. Precocious puberty was observed in one girl; another girl developed multicystic ovaries.CONCLUSION(S): GH treatment was associated with statistically significant growth of the internal genitalia, but remained within the normal range. As altered pubertal development and ovarian morphology were found in 2 of 18 girls, monitoring of puberty and ovarian function during GH therapy in SGA girls is prudent. Altogether, the findings are reassuring. However, long-term effects of GH treatment on adult reproductive function remain unknown.CLINICAL TRIAL REGISTRATION NUMBER: EudraCT 2005-001507-19.

U2 - 10.1016/j.fertnstert.2014.09.014

DO - 10.1016/j.fertnstert.2014.09.014

M3 - Journal article

VL - 102

SP - 1733

EP - 1741

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 6

ER -

ID: 44847419